Orchestra BioMed (OBIO) to Release Earnings on Wednesday

Orchestra BioMed (NASDAQ:OBIO) is anticipated to release its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Orchestra BioMed to post earnings of ($0.44) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 19, 2025 at 9:30 AM ET.

Orchestra BioMed (NASDAQ:OBIO) last released its earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01. The company had revenue of $0.84 million during the quarter, compared to analysts’ expectations of $0.78 million. Orchestra BioMed had a negative return on equity of 289.42% and a negative net margin of 2,367.49%. On average, analysts expect Orchestra BioMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Orchestra BioMed Price Performance

Shares of OBIO stock opened at $3.81 on Monday. The business’s fifty day moving average is $3.08 and its 200 day moving average is $2.96. The company has a quick ratio of 2.09, a current ratio of 2.10 and a debt-to-equity ratio of 48.76. The stock has a market cap of $147.23 million, a price-to-earnings ratio of -2.08 and a beta of 0.65. Orchestra BioMed has a twelve month low of $2.20 and a twelve month high of $6.50.

Institutional Trading of Orchestra BioMed

Institutional investors have recently added to or reduced their stakes in the business. Creative Planning purchased a new position in shares of Orchestra BioMed in the second quarter worth $40,000. XTX Topco Ltd purchased a new position in Orchestra BioMed in the 2nd quarter worth about $45,000. Jane Street Group LLC bought a new position in Orchestra BioMed during the 2nd quarter valued at about $50,000. Bank of America Corp DE boosted its holdings in shares of Orchestra BioMed by 35.7% during the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company’s stock valued at $58,000 after acquiring an additional 5,678 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Orchestra BioMed in the second quarter worth approximately $67,000. 53.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on OBIO shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Orchestra BioMed in a research report on Wednesday, October 8th. Chardan Capital restated a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a report on Wednesday, August 13th. HC Wainwright lowered their target price on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, September 4th. Finally, BTIG Research reissued a “neutral” rating on shares of Orchestra BioMed in a research report on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.50.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.